CASI Pharmaceuticals, Inc. (CASI) EPS Estimated At $-0.07

July 14, 2018 - By Megan Stone

CASI Pharmaceuticals, Inc. (NASDAQ:CASI) LogoInvestors sentiment increased to 2 in Q1 2018. Its up 0.10, from 1.9 in 2017Q4. It increased, as 1 investors sold CASI Pharmaceuticals, Inc. shares while 10 reduced holdings. 10 funds opened positions while 12 raised stakes. 4.96 million shares or 39.41% more from 3.56 million shares in 2017Q4 were reported.
Barclays Plc invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Moors And Cabot invested in 22,935 shares or 0.01% of the stock. 60 were accumulated by Wells Fargo And Mn. Geode Capital Mgmt Ltd Liability Com, Massachusetts-based fund reported 225,578 shares. Alpine Mngmt Ltd stated it has 11,954 shares. Bancshares Of New York Mellon Corporation invested in 0% or 36,880 shares. Deutsche Comml Bank Ag owns 21 shares or 0% of their US portfolio. Jpmorgan Chase Communications stated it has 9 shares. Wellington Shields Cap Mgmt Lc has 0.5% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Everett Harris And Ca, California-based fund reported 10,002 shares. Jefferies Limited Company accumulated 27,000 shares. State Street invested in 0% or 23,629 shares. Vanguard Group reported 0% of its portfolio in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Bluecrest Cap Mngmt Limited has invested 0% in CASI Pharmaceuticals, Inc. (NASDAQ:CASI). Northern Tru has 0% invested in CASI Pharmaceuticals, Inc. (NASDAQ:CASI) for 73,987 shares.

Analysts expect CASI Pharmaceuticals, Inc. (NASDAQ:CASI) to report $-0.07 EPS on August, 13.They anticipate $0.03 EPS change or 75.00 % from last quarter’s $-0.04 EPS. After having $-0.05 EPS previously, CASI Pharmaceuticals, Inc.’s analysts see 40.00 % EPS growth. The stock decreased 3.18% or $0.24 during the last trading session, reaching $7.3. About 278,153 shares traded. CASI Pharmaceuticals, Inc. (NASDAQ:CASI) has risen 585.86% since July 14, 2017 and is uptrending. It has outperformed by 573.29% the S&P500.

CASI Pharmaceuticals, Inc., a late-stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of therapeutics addressing cancer and other unmet medical needs in China. The company has market cap of $628.86 million. The Company’s lead drug candidate is ENMD-2076, an Aurora A/angiogenic kinase inhibitor, which is in multiple Phase II studies in advanced fibrolamellar carcinoma, triple-negative breast cancer, advanced ovarian clear cell carcinomas, and advanced/metastatic soft tissue sarcoma. It currently has negative earnings. The company's late-stage clinical drug candidates, including MARQIBO, a microtubule inhibitor to treat adult patients with philadelphia chromosome-negative acute lymphoblastic leukemia; ZEVALIN injection for intravenous use indicated for the treatment of patients with relapsed or refractory, low-grade, or follicular B-cell non-hodgkin's lymphoma, as well as for the treatment of patients with previously untreated follicular non-hodgkin's lymphoma; and EVOMELA, a melphalan hydrochloride for injection primarily for use as a high-dose conditioning treatment prior to hematopoietic progenitor cell transplantation in patients with multiple myeloma.

More notable recent CASI Pharmaceuticals, Inc. (NASDAQ:CASI) news were published by: which released: “Mid-Day Market Update: Dow Down Over 150 Points; CASI Pharmaceuticals Shares Spike Higher” on June 21, 2018, also with their article: “Benzinga’s Daily Biotech Pulse: Realm Therapeutics To List On Nasdaq, CASI Pharma Added To Russell 2000 Index” published on July 05, 2018, published: “Here’s Why CASI Pharmaceuticals Rose as Much as 31.6% Today” on June 21, 2018. More interesting news about CASI Pharmaceuticals, Inc. (NASDAQ:CASI) were released by: and their article: “Report: Exploring Fundamental Drivers Behind Cabot Oil & Gas, Chesapeake Lodging Trust, CASI Pharmaceuticals …” published on June 25, 2018 as well as‘s news article titled: “Mid-Morning Market Update: Markets Open Lower; Kroger Earnings Beat Expectations” with publication date: June 21, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.